EIF3CL is a component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which mediates multiple critical steps in protein synthesis initiation. The eIF-3 complex associates with the 40S ribosome to facilitate recruitment of initiation factors and formation of the 43S pre-initiation complex, promotes mRNA scanning for AUG recognition, and enables ribosomal recycling following translation termination. EIF3CL selectively regulates translation of mRNAs encoding cell proliferation factors involved in cell cycling, differentiation, and apoptosis through differential RNA stem-loop binding mechanisms. In cancer contexts, EIF3CL expression is upregulated and functionally significant. High EIF3CL expression was identified as a tumor suppressor gene in breast cancer cells treated with high salt, associated with anti-tumor activity and apoptosis induction 1. Conversely, EIF3CL was identified as a required cellular factor for diffuse intrinsic pontine glioma (DIPG) survival, representing a potential therapeutic target 2. In serous ovarian cancer, EIF3CL is upregulated compared to paratumor tissue, with high expression independently associated with poor overall survival, establishing it as a poor prognostic biomarker 3. EIF3CL expression is also induced during early lentiviral transduction 4 and modulated by vitamin D3 metabolites in placental cells 5, suggesting broader roles in cellular stress responses and viral interactions.